Home
Contact
Publications
A Phase 1 Dose Escalation Study of the Oncolytic Adenovirus Enadenotucirev, Administered Intravenously to Patients with Epithelial Solid Tumors (EVOLVE)
5th February 2019
Kate Wright
Enadenotucirev Clinical
Click here for Full Text
Share this Story
Facebook
Twitter
LinkedIn
Reddit
Digg
Delicious
Google++
E-Mail+
About the Author
Comments are closed.
Prev Post
Next Post
Filter Publications
Enadenotucirev Preclinical
Enadenotucirev Clinical
T-SIGn
Reviews
See All Publications
© Copyright 2021 PsiOxus Therapeutics
RSS
Back to Top
About
Vision & Strategy
Our People
T-SIGn Platform Technology
Pipeline
Publications and Posters
Partners and Investors
News and Events
Careers
Contact Us
Menu
Comments are closed.